Merck Surges 44%, Outperforming Peers in Pharma Sector

Merck has outperformed its peers in the pharma sector with a year-to-date gain of 44%, making it the leader among US drugmakers. This impressive performance is driven by the company's strong oncology portfolio, particularly the top-selling cancer drug KEYTRUDA, and its diverse product lineup beyond obesity drugs.

Amgen comes in second with a broad product lineup and a promising obesity drug in late-stage development, while Pfizer trails behind but remains attractive to income investors due to its 6.3% dividend yield.

The ongoing obesity drug race is expected to continue shaping the pharmaceutical landscape, and investors are advised to watch upcoming pipeline data and regulatory decisions for further insights into the sector's dynamics.